Free Trial

Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $89.90

Janux Therapeutics logo with Medical background

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned an average recommendation of "Buy" from the twelve brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $89.90.

Several analysts have issued reports on JANX shares. HC Wainwright boosted their target price on Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a research note on Tuesday, December 3rd. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Leerink Partners increased their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 3rd. Scotiabank boosted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a research report on Wednesday, December 4th. Finally, UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $69.00 price objective for the company.

Get Our Latest Stock Analysis on JANX

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $46.24, for a total value of $44,297.92. Following the transaction, the insider now owns 6,887 shares of the company's stock, valued at $318,454.88. This represents a 12.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David Alan Campbell sold 15,000 shares of the firm's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the sale, the chief executive officer now owns 242,054 shares in the company, valued at approximately $16,217,618. This trade represents a 5.84 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 192,032 shares of company stock valued at $9,512,515. 29.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. boosted its holdings in shares of Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after purchasing an additional 7,442 shares in the last quarter. Virtu Financial LLC boosted its stake in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after buying an additional 2,419 shares in the last quarter. Neo Ivy Capital Management bought a new position in Janux Therapeutics during the third quarter valued at approximately $940,000. Geode Capital Management LLC raised its stake in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after acquiring an additional 38,490 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after acquiring an additional 144,883 shares during the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Up 0.1 %

JANX traded up $0.08 during trading on Friday, hitting $56.83. 1,251,821 shares of the company traded hands, compared to its average volume of 788,634. Janux Therapeutics has a one year low of $7.79 and a one year high of $71.71. The stock's fifty day moving average is $53.89 and its 200 day moving average is $47.06. The firm has a market cap of $2.98 billion, a P/E ratio of -48.57 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics's quarterly revenue was down 82.6% on a year-over-year basis. On average, equities research analysts forecast that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

About Janux Therapeutics

(Get Free Report

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Articles

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Should you invest $1,000 in Janux Therapeutics right now?

Before you consider Janux Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.

While Janux Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines